A Phase IB/II Study of Epacadostat (INCB024360) in Combination With Pembrolizumab (MK-3475) and Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer

Trial Profile

A Phase IB/II Study of Epacadostat (INCB024360) in Combination With Pembrolizumab (MK-3475) and Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs Azacitidine (Primary) ; Epacadostat (Primary) ; Pembrolizumab (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 11 Dec 2017 Planned End Date changed from 30 Jun 2020 to 30 Jul 2020.
    • 11 Dec 2017 Planned primary completion date changed from 30 Jun 2019 to 30 Jul 2019.
    • 11 Dec 2017 Planned initiation date changed from 31 Oct 2017 to 31 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top